Budesonide/glycopyrronium/formoterol fumarate triple therapy prevents pulmonary hypertension in a COPD mouse model via NFκB inactivation

Budesonide/glycopyrronium/formoterol fumarate triple therapy prevents pulmonary hypertension in a COPD mouse model via NFκB inactivation

Abstract Background Chronic obstructive pulmonary disease (COPD) is a health problem that results in death, commonly due to the development of pulmonary hypertension (PH). Here, by utilizing a mouse model of intratracheal elastase-induced emphysema that presents three different phases of COPD, we so...

Full description

Bibliographic Details
Main Authors: Ratoe Suraya, Tatsuya Nagano, Gusty Rizky Teguh Ryanto, Wiwin Is Effendi, Daisuke Hazama, Naoko Katsurada, Masatsugu Yamamoto, Motoko Tachihara, Noriaki Emoto, Yoshihiro Nishimura, Kazuyuki Kobayashi
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Respiratory Research
Subjects:
Chronic obstructive pulmonary disease
Pulmonary hypertension
Budesionde
Glycopyrronium
Formoterol fumarate
NFκB
Online Access:https://doi.org/10.1186/s12931-022-02081-y

Internet

https://doi.org/10.1186/s12931-022-02081-y

Similar Items